{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:04:29Z","timestamp":1793124269000,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jjcc.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T02:45:03Z","timestamp":1664765103000},"page":"337-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Emerging roles of protease-activated receptors in cardiometabolic disorders"],"prefix":"10.1016","volume":"81","author":[{"given":"Tomoya","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2022.09.013_bb0005","first-page":"631","article-title":"Atherosclerotic plaque inflammation: the final frontier?","volume":"20","author":"Aikawa","year":"2004","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0010","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0025","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"issue":"23 Suppl. 1","key":"10.1016\/j.jjcc.2022.09.013_bb0030","first-page":"Iii20-6","article-title":"Inflammation in atherosclerosis and implications for therapy","volume":"109","author":"Paoletti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0035","first-page":"254","article-title":"Inflammation, sepsis, and coagulation","volume":"84","author":"Esmon","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0040","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/01.CIR.0000131660.51520.9A","article-title":"Bidirectional relation between inflammation and coagulation","volume":"109","author":"Levi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0050","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.105.574830","article-title":"Protease-activated receptors in cardiovascular diseases","volume":"114","author":"Leger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0055","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00062752-200701000-00011","article-title":"Intertwining of thrombosis and inflammation in atherosclerosis","volume":"14","author":"Croce","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0065","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.ATV.0000070100.47907.26","article-title":"Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice","volume":"23","author":"Major","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1532\/IJH97.03165","article-title":"Progress in the understanding of protease-activated receptors","volume":"79","author":"Gabazza","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1160\/TH07-08-0481","article-title":"Thrombin and protease-activated receptors (PARs) in atherothrombosis","volume":"99","author":"Martorell","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood.V96.2.554.014k17_554_559","article-title":"The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation","volume":"96","author":"Franco","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0090","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.4049\/jimmunol.180.11.7368","article-title":"C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome","volume":"180","author":"Kambas","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0095","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/ATVBAHA.107.161471","article-title":"Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates","volume":"28","author":"Brambilla","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0105","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1160\/TH14-10-0830","article-title":"Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation","volume":"114","author":"Brambilla","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0110","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/db09-1008","article-title":"Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin","volume":"59","author":"Gerrits","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0115","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/01.ATV.15.5.612","article-title":"Transcriptional regulation of tissue factor expression in human endothelial cells","volume":"15","author":"Parry","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.thromres.2018.06.020","article-title":"Tissue factor (: factor VIIa) in the heart and vasculature: more than an envelope","volume":"168","author":"D'Alessandro","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0125","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/CIRCULATIONAHA.109.907121","article-title":"Early atherosclerosis exhibits an enhanced procoagulant state","volume":"122","author":"Borissoff","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2006-933336","article-title":"Sources of tissue factor","volume":"32","author":"\u00d8sterud","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0037-1614040","article-title":"Macrophages synthesize factor X and secrete factor X\/Xa-containing prothrombinase activity into the surrounding medium","volume":"84","author":"Pejler","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0140","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2007-06-096651","article-title":"The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells","volume":"110","author":"Bae","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055784","article-title":"Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner","volume":"8","author":"Borissoff","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/ATVBAHA.109.188656","article-title":"Activated protein C protects against myocardial ischemia\/ reperfusion injury via inhibition of apoptosis and inflammation","volume":"29","author":"Loubele","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1538-7836.2011.04331.x","article-title":"Activated protein C protects against myocardial ischemic\/reperfusion injury through AMP-activated protein kinase signaling","volume":"9","author":"Wang","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0160","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2017-10-810895","article-title":"PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke","volume":"131","author":"Sinha","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0165","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/nm1667","article-title":"Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis","volume":"13","author":"Isermann","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","article-title":"PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells","volume":"120","author":"Boire","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0175","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2012-09-355958","article-title":"Matrix metalloproteases and PAR1 activation","volume":"121","author":"Austin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0180","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2016-06-724245","article-title":"A novel mechanism regulating human platelet activation by MMP-2-mediated PAR1 biased signaling","volume":"129","author":"Sebastiano","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0185","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.111.066787","article-title":"\u03b2-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells","volume":"125","author":"Jaffr\u00e9","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0190","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI119658","article-title":"Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2","volume":"100","author":"Corvera","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0195","doi-asserted-by":"crossref","first-page":"26089","DOI":"10.1074\/jbc.M703840200","article-title":"Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia","volume":"282","author":"Knecht","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0200","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2015-11-683110","article-title":"Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteolysis and signaling","volume":"127","author":"Le Gall","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0205","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.ATV.0000128849.12617.f4","article-title":"Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress","volume":"24","author":"Meir","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0210","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1161\/01.ATV.0000246797.05781.ad","article-title":"Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice","volume":"26","author":"Bea","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0215","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0220","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: a new oral thrombin inhibitor","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-012-6411-3","article-title":"The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis","volume":"26","author":"Kadoglou","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/jpet.112.194837","article-title":"The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice","volume":"343","author":"Lee","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5114\/aoms.2014.40742","article-title":"Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice","volume":"10","author":"Pingel","year":"2014","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0240","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.2147\/DDDT.S86969","article-title":"Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice","volume":"9","author":"Preusch","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0245","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.3390\/cells10123517","article-title":"Pleiotropic effects of the protease-activated receptor 1 (PAR1) inhibitor, vorapaxar, on atherosclerosis and vascular inflammation","volume":"10","author":"Friebel","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2019.106632","article-title":"Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice","volume":"124","author":"Rahadian","year":"2020","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0255","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.118.310967","article-title":"Noncanonical matrix metalloprotease 1-protease-activated receptor 1 signaling drives progression of atherosclerosis","volume":"38","author":"Rana","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0260","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.107.692764","article-title":"Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy","volume":"116","author":"Pawlinski","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0265","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1172\/JCI92744","article-title":"Thrombin promotes diet-induced obesity through fibrin-driven inflammation","volume":"127","author":"Kopec","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0270","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.114.218545","article-title":"Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice","volume":"351","author":"Kopec","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0280","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0285","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a direct oral factor xa inhibitor, attenuates atherosclerosis by alleviating factor xa-PAR2-mediated autophagy suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.739212","article-title":"Rivaroxaban suppresses atherosclerosis by inhibiting FXa-induced macrophage M1 polarization-mediated phenotypic conversion of vascular smooth muscle cells","volume":"8","author":"Ma","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0295","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/s41598-019-40602-w","article-title":"Targeting coagulation factor xa promotes regression of advanced atherosclerosis in apolipoprotein-E deficient mice","volume":"9","author":"Posthuma","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0300","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0305","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/ATVBAHA.117.310082","article-title":"PAR2 (protease-activated receptor 2) deficiency attenuates atherosclerosis in mice","volume":"38","author":"Jones","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0310","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1253\/circj.CJ-15-0285","article-title":"Effects of the factor xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"79","author":"Zuo","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0315","doi-asserted-by":"crossref","first-page":"43079","DOI":"10.1038\/srep43079","article-title":"Parenteral administration of factor Xa\/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis","volume":"7","author":"Moran","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2017.12.037","article-title":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury","volume":"820","author":"Hara","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0325","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0330","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ijcard.2016.06.212","article-title":"Rivaroxaban, a factor xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice","volume":"220","author":"Goto","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0335","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2018.05.015","article-title":"The factor xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction","volume":"167","author":"Bode","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0340","doi-asserted-by":"crossref","first-page":"915","DOI":"10.5551\/jat.48405","article-title":"Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction","volume":"26","author":"Liu","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0345","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1253\/circj.CJ-20-1006","article-title":"Activated factor X signaling pathway via protease-activated receptor 2 is a novel therapeutic target for preventing atrial fibrillation","volume":"85","author":"Matsuura","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0350","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1161\/ATVBAHA.116.307883","article-title":"Coagulation factor xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy","volume":"36","author":"Oe","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0355","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.118.033544","article-title":"Protease-activated receptor-2 plays a critical role in vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice","volume":"138","author":"Hara","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0360","doi-asserted-by":"crossref","first-page":"11206","DOI":"10.1038\/s41598-019-47474-0","article-title":"Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice","volume":"9","author":"Pham","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0365","doi-asserted-by":"crossref","first-page":"10574","DOI":"10.1074\/jbc.RA118.003491","article-title":"Protease-activated receptor 1 inhibits cholesterol efflux and promotes atherogenesis via cullin 3-mediated degradation of the ABCA1 transporter","volume":"293","author":"Raghavan","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0370","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41418-020-00623-9","article-title":"Thrombin-Par1 signaling axis disrupts COP9 signalosome subunit 3-mediated ABCA1 stabilization in inducing foam cell formation and atherogenesis","volume":"28","author":"Boro","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0375","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.ajpath.2011.07.015","article-title":"Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet","volume":"179","author":"Kassel","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0380","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/ajpath.2010.090672","article-title":"Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice","volume":"176","author":"Luyendyk","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0385","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fphar.2017.00647","article-title":"Protease-activated receptor-2 deficiency attenuates atherosclerotic lesion progression and instability in apolipoprotein E-deficient mice","volume":"8","author":"Zuo","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0390","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/ATVBAHA.110.213280","article-title":"Protease-activated receptor 2 deficiency reduces cardiac ischemia\/reperfusion injury","volume":"30","author":"Antoniak","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0395","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm.2461","article-title":"Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation","volume":"17","author":"Badeanlou","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0400","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ajpath.2014.10.008","article-title":"Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice","volume":"185","author":"Wang","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0405","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000515","article-title":"Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"3","author":"Douxfils","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0410","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.thromres.2014.08.010","article-title":"The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation","volume":"134","author":"Incampo","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0415","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1093\/eurheartj\/ehz301","article-title":"Myocardial injury after non-cardiac surgery: diagnosis and management","volume":"41","author":"Devereaux","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0420","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/S0140-6736(18)30832-8","article-title":"Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial","volume":"391","author":"Devereaux","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0425","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1021\/jm0603670","article-title":"Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects","volume":"49","author":"Chackalamannil","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0430","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1021\/jm0502236","article-title":"Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents","volume":"48","author":"Chackalamannil","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0435","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0440","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0445","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.114.015042","article-title":"Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack: results from TRA 2\u00b0P-TIMI 50","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0450","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001505","article-title":"Efficacy and safety of vorapaxar as approved for clinical use in the United States","volume":"4","author":"Magnani","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0455","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.115.019861","article-title":"Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0460","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0465","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1358863X19892690","article-title":"Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2\u00b0P-TIMI 50 trial","volume":"25","author":"Qamar","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0470","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(96)11189-2","article-title":"Tissue-factor antigen and activity in human coronary atherosclerotic plaques","volume":"349","author":"Ardissino","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0021-9150(97)00132-9","article-title":"Localization and activity of tissue factor in human aortic atherosclerotic lesions","volume":"133","author":"Hatakeyama","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0480","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0485","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0490","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0495","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.09.013_bb0500","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1042\/BST20200191","article-title":"The development of proteinase-activated receptor-2 modulators and the challenges involved","volume":"48","author":"McIntosh","year":"2020","journal-title":"Biochem Soc Trans"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722002453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508722002453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:58Z","timestamp":1760274478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508722002453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0914508722002453"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.09.013","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging roles of protease-activated receptors in cardiometabolic disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}